Alizadeasl Azin, Abdi Seifollah, Firouzi Ata, Pouraliakbar Hamidreza, Sadeghipour Parham, Azarfarin Rasoul, Parsa Niloufar Akbari
Cardio-Oncology Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.
Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.
J Tehran Heart Cent. 2024 Apr;19(2):141-146. doi: 10.18502/jthc.v19i2.16206.
Few cases of transcatheter aortic valve implantation (TAVI) following infective endocarditis (IE) have been reported. In this presentation, we discuss the feasibility of TAVI in a degenerated bioprosthetic valve affected by IE. We examine a rare case involving an elderly man with a degenerated bioprosthetic aortic valve complicated by IE 6 months after a COVID-19 infection. The patient was successfully treated with valve-in-valve intervention following antibiotic therapy for the acute phase of the infection. This resulted in excellent outcomes with no complications in the early postprocedural period and during follow-up visits. For patients with a destructed bioprosthetic aortic valve due to IE and residual dysfunction after healing, valve-in-valve intervention can be a safe and effective treatment option, particularly for those at high risk for surgery.
感染性心内膜炎(IE)后经导管主动脉瓣植入术(TAVI)的病例报道较少。在本报告中,我们讨论了TAVI在受IE影响的退化生物瓣膜中的可行性。我们研究了一例罕见病例,该老年男性在感染COVID-19 6个月后,其退化的生物人工主动脉瓣并发IE。患者在感染急性期接受抗生素治疗后,成功接受了瓣中瓣介入治疗。这带来了极佳的结果,术后早期及随访期间均无并发症。对于因IE导致生物人工主动脉瓣破坏且愈合后仍有残余功能障碍的患者,瓣中瓣介入治疗可能是一种安全有效的治疗选择,尤其是对于手术高危患者。